UNLIMITED TURBO LONG - ASTRAZENECA | Market Closed - Deutsche Boerse AG 11:21:09 2024-06-24 am EDT | ||
| 4.67 EUR | -0.21% |
|
| Current month | +7.60% | ||
| 1 month | +3.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 4.67 | -0.21% |
| 24-06-21 | 4.68 | +3.08% |
| 24-06-20 | 4.54 | +0.22% |
| 24-06-19 | 4.53 | -1.09% |
| 24-06-18 | 4.58 | -0.65% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 11:21 am EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PN3EBK |
| ISIN | DE000PN3EBK8 |
| Date issued | 2023-05-16 |
| Strike | 8,609 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.68 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.9 € |
|---|---|
| Lowest since issue | 1.3 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.4
USD
Average target price
174.4
USD
Spread / Average Target
+10.15%
- Stock Market
- Certificates
- Certificat
